Rheumatoid Arthritis Drugs Market Share, Development, Growth to 2023

Rheumatoid Arthritis Drugs Market Size, Share, Trends, Company Profiles,

Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation

and Forecast To 2023

Summary

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and

deformity of the joints . It affects over seven million individuals in the 10MM covered in this

report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the

prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have

been effective in treating the signs and symptoms of RA and inhibiting progression to erosive

bone disease. However, the landscape is quickly changing with the introduction of biosimilars,

novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change

the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective

therapies for RA, the market is extremely competitive for new entrants and will undergo further

pressure as biosimilars are approved and launch.

Highlights

Key Questions Answered

- How large an impact will biosimilars have on the RA market? What do rheumatologists and

key opinion leaders across the 10MM think about the evolving RA treatment landscape?

- How is the uptake of JAK inhibitors expected to affect the global RA market?

- Which novel biologics are the most promising? How are product launches expected to affect

the anti-TNFs?

Browse full report on: http://www.radiantinsights.com/research/pharmapoint-rheumatoidarthritis-global-drug-forecast-and-market-analysis-to-2023

- According to KOLs, what are the most important unmet needs in RA? Will these needs be

addressed by pipeline agents? What needs will remain by the end of the forecast period in 2023?

- What governmental and industry developments are likely to affect sales of the top-selling RA

drugs in the markets researched? Which is the largest growth market globally?

Key Findings

- Biosimilars are expected...